Nephropathy Clinical Trials

7 recruiting

Nephropathy Trials at a Glance

112 actively recruiting trials for nephropathy are listed on ClinicalTrialsFinder across 6 cities in 54 countries. The largest study group is Phase 2 with 27 trials, with the heaviest enrollment activity in Houston, Beijing, and Beijing. Lead sponsors running nephropathy studies include Novartis Pharmaceuticals, Alexion Pharmaceuticals, Inc., and Chinese PLA General Hospital.

Browse nephropathy trials by phase

Treatments under study

About Nephropathy Clinical Trials

Looking for clinical trials for Nephropathy? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Nephropathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Nephropathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 112 trials

Recruiting
Phase 2

Chinese Adults With Kidney Disease

Immunoglobulin A Nephropathy (IgAN)IC-MPGNComplement 3 Glomerulopathy (C3G)
ADARx Pharmaceuticals, Inc.30 enrolled10 locationsNCT07522099
Recruiting
Phase 1

A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

Primary Membranous Nephropathy
Shanghai Jiaolian Drug Research and Development Co., Ltd52 enrolled6 locationsNCT05668403
Recruiting
Phase 2

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

Primary Membranous Nephropathy
Climb Bio, Inc.45 enrolled45 locationsNCT07096843
Recruiting
Phase 3

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled228 locationsNCT06935357
Recruiting

Mixed Methods Study of Health-Related Social Needs in African American Adults With Chronic Kidney Disease and Type 2 Diabetes Mellitus

Chronic Kidney DiseasesDiabetes Mellitus, Type 2Diabetic Nephropathy Type 2 - Uncontrolled
Medical College of Wisconsin330 enrolled1 locationNCT05692388
Recruiting
Phase 2Phase 3

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated176 enrolled86 locationsNCT07204275
Recruiting
Phase 2

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

Glomerulonephritis, IGAImmunoglobulin A Nephropathy
Novartis Pharmaceuticals20 enrolled18 locationsNCT06797518
Recruiting
Phase 3

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

Primary Membranous Nephropathy
Biogen180 enrolled91 locationsNCT06962800
Recruiting
Phase 2

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

IgA Nephropathy (IgAN)IgANC3G+2 more
ADARx Pharmaceuticals, Inc.45 enrolled25 locationsNCT06989359
Recruiting
Phase 2

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

Primary Membranous Nephropathy
Alexion Pharmaceuticals, Inc.30 enrolled40 locationsNCT07157787
Recruiting
Phase 3

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A NephropathyIgAN
Alexion Pharmaceuticals, Inc.510 enrolled267 locationsNCT06291376
Recruiting
Phase 1Phase 2

A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.

Immunoglobulin A Nephropathy
Beijing Mabworks Biotech Co., Ltd.130 enrolled1 locationNCT07375758
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

Primary IgA Nephropathy
Hoffmann-La Roche428 enrolled202 locationsNCT05797610
Recruiting

Family Investigation of Nephropathy and Diabetes (F.I.N.D.)

Diabetes MellitusAlbuminuriaDiabetic Kidney Disease+1 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)100,000 enrolled1 locationNCT00342927
Recruiting

IgA Nephropathy Biomarkers Evaluation Study (INTEREST)

IgA NephropathyGlomerular Diseases
Sun Yat-sen University2,000 enrolled1 locationNCT02954419
Recruiting
Phase 4

Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy

Primary Membranous Nephropathy
First Affiliated Hospital, Sun Yat-Sen University116 enrolled1 locationNCT06573411
Recruiting
Early Phase 1

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07507201
Recruiting
Phase 2

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals32 enrolled8 locationsNCT07146906
Recruiting
Phase 2

Study of WAL0921 in Patients With Glomerular Kidney Diseases

Diabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change Disease+2 more
Walden Biosciences96 enrolled50 locationsNCT06466135
Recruiting
Phase 3

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

Primary Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals31 enrolled15 locationsNCT06994845